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Toward a Sensible Single-antigen Bead Cutoff 
Based on Kidney Graft Survival
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The complement-dependent cytotoxicity crossmatch (CDC-XM) assays and the much more sensitive 
Luminex technology are commonly used for the detection 
of anti-HLA antibodies. The presence of donor-specific 
anti-HLA antibodies (DSA) detected by the CDC-XM is con-
sidered a contraindication for transplant. It is widely known 
that single-antigen bead (SAB) assays can detect DSAs when 
the CDC-XM result is negative. The clinical relevance of the 
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Background. There is no consensus in the literature on the interpretation of single-antigen bead positive for a specific 
HLA antibody. Methods. To inform the debate, we studied the relationship between various single-antigen bead positiv-
ity algorithms and the impact of resulting donor-specific HLA antibody (DSA) positivity on long-term kidney graft survival in 
3237 deceased-donor transplants. Results. First, we showed that the interassay variability can be greatly reduced when 
working with signal-to-background ratios instead of absolute median fluorescence intensities (MFIs). Next, we determined 
pretransplant DSA using various MFI cutoffs, signal-to-background ratios, and combinations thereof. The impact of the vari-
ous cutoffs was studied by comparing the graft survival between the DSA-positive and DSA-negative groups. We did not 
observe a strong impact of various cutoff levels on 10-year graft survival. A stronger relationship between the cutoff level 
and 1-year graft survival for DSA-positive transplants was found when using signal-to-background ratios, most pronounced 
for the bead of the same HLA locus with lowest MFI taken as background. Conclusions. With respect to pretransplant 
risk stratification, we propose a signal-to-background ratio-6 (using the bead of the same HLA-locus with lowest MFI as 
background) cutoff of 15 combined with an MFI cutoff of 500, resulting in 8% and 21% lower 1- and 10-year graft survivals, 
respectively, for 8% DSA-positive transplants.
(Transplantation 2019;103: 789–797
Transplantation
TP
TPA
0041-1337/18/0000-0000
Lippincott Williams & WilkinsHagerstown, MD
10.1097/TP.0000000000002357
Wisse et al
xxxxxx
xxxApril2019
4
2018
LWW
6 Department of Nephrology, University of Groningen, University Medical Center 
Groningen, Groningen, The Netherlands.
7 Department of Laboratory Medicine, University of Groningen, University 
Medical Center Groningen, Groningen, The Netherlands.
8 Department of Transplantation Immunology, Tissue Typing Laboratory, 
Maastricht University Medical Center, Maastricht, The Netherlands.
9 Division of Nephrology, Department of Internal Medicine, Maastricht University 
Medical Center, Maastricht, The Netherlands.
10 Amsterdam University Medical Center, Vrije Universiteit Amsterdam, 
Department of Nephrology, Amsterdam Cardiovascular Sciences, Amsterdam, 
The Netherlands.
11 Department of Immunogenetics, Sanquin Diagnostic Services, Amsterdam, 
The Netherlands.
Copyright © 2018 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.<zdoi;10.1097/TP.0000000000002357>
790 Transplantation  ■  April 2019  ■ Volume 103  ■  Number 4 www.transplantjournal.com
antibodies detected by the much more sensitive SAB assays 
is less clear, however,1 and their presence is generally consid-
ered to be a risk factor rather than a contraindication.2
In the Dutch PROCARE Consortium study, the impact 
of SAB-detected DSA on graft survival was determined for 
all kidney transplants performed between 1995 and 2006, 
for which pretransplant serum was available.3 The impact 
was most pronounced in the 3237 deceased-donor trans-
plants, where the 1- and 10-year graft survivals were 5% 
and 16%, respectively, lower in patients with SAB-detected 
DSA in pretransplant sera (N = 430, 13% DSA positive).
In the assessment of SAB bead positivity, initially, the 
manufacturer’s instructions were followed. In the litera-
ture, there is no consensus, however, on the interpretation 
of these SAB measurements, and there is disagreement on 
the cutoff value for specific antibodies. This is partly due 
to the high interassay and interlaboratory variability of the 
SAB measurements.4 Second, and more importantly, con-
trary to expectations of many, the fluorescence intensity 
has only a weak relationship with titer of the specific anti-
body in the tested serum1,5 and is influenced by many other 
factors other than the amount of specific antibody bound 
to the bead.
We had the opportunity to investigate the relationship 
between the fluorescence levels measured in pretransplant sera 
on the one hand, and clinical relevance as expressed by graft 
survival on the other hand, for a large cohort of CDC-XM–
negative kidney transplants performed in the Netherlands 
between 1995 and 2006. All SAB measurements were per-
formed in 1 central laboratory, using the same machine, bead 
lot, and by a team of 2 highly trained technicians, keeping the 
assay variability at a minimum. We agree with recent publica-
tions stressing that the interpretation of SAB measurements 
needs to be made in the context of the patient’s specifics, his/
her history, and other available measurements.6 The findings 
of the current rather mechanistic investigation will therefore 
be informative for general risk stratification rather than for 
risk assessment of an individual patient.
MATERIALS AND METHODS
Interlaboratory Variability
To assess the interlaboratory variability, we have 
included 12 Eurotransplant Reference Laboratory 
External Proficiency Testing sera evaluated in 2016 with 
HLA class I and class II SAB by HLA laboratories in the 
Eurotransplant region. Of the 12 reference sera, 11 were 
positive for HLA class I antibodies and 8 for HLA class II 
antibodies. Here, we have included the measurements of 
3 laboratories in the Netherlands using the same SAB kit 
manufacturer as for our multicenter study.
Patients, Sera, and Clinical Data
This multicenter study included all 6097 kidney trans-
plants performed between January 1995 and December 
2005 in all Dutch transplant centers. In all cases, the T cell 
and/or unseparated CDC-XM with current and historic 
peak sera were negative. Historic cytotoxic HLA antibod-
ies were assigned as unacceptable for allocation within the 
Eurotransplant region. Bead assay–defined DSA were not 
considered (as risk factor) in the matching procedure at that 
time, nor had these DSA influence on immunosuppressive 
treatment. Informed consent for data collection and use of 
leftover sera was obtained from all subjects. Patients and 
donors investigated were predominantly white. The use 
of sera and experimental protocols was approved by the 
research ethics committee for Biobanks and the medical 
ethics committee of the University Medical Center Utrecht. 
Moreover, this study was performed in accordance with 
the FEDERA code of conduct.
We obtained baseline and clinical follow-up transplant 
data from the Netherlands Organ Transplant Registry, 
which was over 95% complete at the time of this study. 
Clinical follow-up was recorded at 3 and 12 months, and 
yearly thereafter for at least 10 years after transplant. The 
primary endpoint of the study is graft failure, defined as 
loss of kidney function when the patient returns to dialysis 
or receives a retransplant. In the analysis of death-censored 
graft failure, recipients who died with a functioning graft 
were censored at the time of death.
Pretransplant patient sera could be collected from 
4787 (78%) transplants of 4585 patients (some patients 
underwent more than 1 transplant). Seventeen transplants 
were lost to follow-up (Netherlands Organ Transplant 
Registry), and 46 transplants were excluded because the 
kidney failed during surgery or shortly thereafter due to 
technical nonimmunological problems. Four thousand 
seven hundred twenty-four transplants were included in 
the analysis, of which 3237 were performed with grafts 
from deceased donors.
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Detection and Definition of Donor-specific Anti-HLA 
Antibodies
The presence of HLA antibodies in the pretransplant 
sera, used for pretransplant crossmatch, was assessed 
retrospectively in 1 central laboratory as described previ-
ously.7 Four thousand one hundred eighty-three (89%) of 
4724 of the sera were taken within 3 months pretrans-
plant, 377 (8%) of 4724 were taken 3 to 6 moths pre-
transplant, and only 164 (3%) of 4724 were taken 6 to 
12 months pretransplant. In brief, sera were first tested 
for the presence of HLA class I and class II antibodies 
using Lifecodes LifeScreen Deluxe (Immucor Transplant 
Diagnostics, Stamford, CT). Subsequently, the sera posi-
tive for HLA class I and/or class II were analyzed using 
Lifecodes SAB assay class I and/or II kits (Immucor 
Transplant Diagnostics) to determine the exact specific-
ity of the HLA antibodies. The LABScan 100 flow ana-
lyzer (One Lambda, Canoga Park, CA) was used for data 
acquisition. Bead positivity assignment, the subject of this 
study, was evaluated for a range of median fluorescence 
intensities (MFIs) (median and 5%-trimmed mean), signal-
to-background ratio (STBR) cutoffs (Table 1), and combi-
nations thereof. The presence of SAB-DSA was determined 
by comparing the SAB-HLA-A/B/DR/DQB antibody spe-
cificities on serological level with the split level HLA-A/B/
DR/DQB typing of the donor.
Statistical Analysis
Death-censored graft survival was assessed using the 
adjusted Kaplan-Meier estimator based on inverse prob-
ability weighting.8 The following covariates were consid-
ered for adjustment: recipient and donor age, recipient and 
donor sex, year of transplant, type of donor, cold ischemia 
time, retransplant, graft function, use of IL-2 receptor 
blocker, number of HLA-A/B/DR mismatches, transplant, 
and highest percent PRA.3 We adjusted for recipient age 
(quadratic) and donor age (quadratic), donor type (living 
or deceased; for the total cohort only), cold ischemia time 
(for donation after brain death and donation after cardiac 
death), and induction therapy with IL-2 receptor blocker. 
Two hundred twenty-six missing cold ischemia times were 
imputed using Markov chain Monte Carlo single imputa-
tion; no additional values were missing. Statistical analyses 
were performed with R (version 3.3.2) and SAS (version 
9.4; SAS Institute, Cary, NC) software.
RESULTS
Stabilizing the Fluorescence Measurements
We investigated the direct relationship between fluores-
cence measurements in Luminex SAB assays and clinical 
relevance as expressed by graft survival. The fluorescence 
intensity measured per bead type per sample is highly vari-
able, and in addition, a few beads of the same type from 
a previous sample can accidentally be carried over by the 
measuring device. To stabilize the signal and mitigate the 
effect of beads carried over, typically minimally 60 fluores-
cence measurements are obtained per bead type per sam-
ple and subsequently summarized as either the median or 
5% trimmed mean of those measurements. Both the 5% 
trimmed mean and median values are abbreviated as MFI 
from the literature; we know also that these MFI values 
can be highly variable, with studies reporting a coefficient 
of variation (standard deviation of repeated measurements 
divided by the average value) of 65% between laborato-
ries.4 From personal experience, we know that repeated 
SAB measurements can show a systematic and seemingly 
proportional bias between Luminex machines, lots, and 
test days. A proportional bias can be mitigated by the 
employment of an STBR (Table 1).
To assess whether interassay variability can be reduced 
by working with STBRs, we have determined the variabil-
ity of MFI measurements and compared that with the vari-
ability of various STBRs for a set of 12 External Proficiency 
TABLE 1.
Description of the various signal-to-background ratios with the background used for the calculation
Signal-to-background Ratios Background Calculation
STBR-1 Negative control bead coated with 
human transferrin
MFI of aspecific bead
MFI of the negative controlbead
STBR-2 Lowest assay measurement
MFI of aspecific bead
MFI of the lowestbead
STBR-3 Lowest 3 assay measurements
MFI of aspecific bead
Average MFI of the lowest3beads
STBR-4 Lowest 5 assay measurements
MFI of aspecific bead
Average MFI of the lowest5 beads
STBR-5 Lowest 10 assay measurements
MFI of aspecific bead
Average MFI of the lowest10beads
STBR-6 Bead of the same HLA locus with 
lowest MFI
MFI of aspecific bead
Bead of the same HLA locus with lowest MFI
STBR-7 Positive control bead coated with 
human IgG
MFI of aspecific bead
MFI of the positive controlbead
STBR-8 Negative control bead coated with 
human transferrin
The relative position of the MFI of a specific bead between the 
negative (set to 0) and the positive control bead (set to 1)
MFI, median fluorescence intensity; STBR, signal-to-background ratio.
Copyright © 2018 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
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Testing sera evaluated in 3 laboratories in the Netherlands. 
Only 1 of these 3 laboratories could recover 5% trimmed 
mean values in addition to the MFIs. Even though the 
trimmed mean values tend to be less variable than their 
median counterparts in our experience (data not shown), 
we were unable to evaluate this here. In the remainder of 
this article, MFI will therefore refer to median fluorescence 
intensities, unless explicitly stated otherwise. In addition, 
1 laboratory could not provide the measurements of the 
negative and positive control beads, which resulted in 
the absence of these controls as background in the cur-
rent evaluation of interassay variability. The results of the 
interlaboratory comparison are given in Table 2 for HLA 
class I SAB and in Table 3 for HLA class II.
We calculated the mean absolute relative difference 
(MARD) using the absolute difference in MFI for each 
HLA bead between lab 1 and lab 2 divided by the aver-
age MFI between lab 1 and lab 2. Simplified example: the 
MARD of +25 and −23 is 24. For SAB class I beads, we 
found a MARD in MFI measurement between 2 labora-
tories ranging from 21% (lab 1 vs lab 2) to 51% (lab 1 
vs lab 3) in the critical range of average MFIs between 
500 and 5000. For the ratios, the MARD between the 3 
laboratories was consistently smaller, with values between 
14% and 34%. Also, the mean coefficient of variation 
(MCV) was lower for the STBRs (values between 16% and 
18%) than for the raw MFI (23%). Within the group of 
STBRs, generally more stable results (the smallest MARD 
and MCV) were obtained when more of the lowest ranked 
beads were used to derive a background fluorescence. 
Normalizing by the MFI of the bead of the same HLA 
locus with lowest MFI (which can be loosely interpreted 
as the bead coated with a self-antigen) had comparable 
performance to normalizing by 1 or 3 of the beads with 
lowest MFI in the assay, independent of locus. The biggest 
difference in MFI measurements was found between labo-
ratories 1 and 3. When plotting the SAB class I MFIs of 
these 2 laboratories against each other (Figure  1A), we 
found lab 3 to consistently measure higher values than 
lab 1. In Figure 1B, STBR-6 ratio (using bead of the same 
HLA locus with lowest MFI as background) for the same 
measurements is depicted. We found that the measurement 
bias from Figure 1A is not present anymore in the STBR-6 
ratio measurements. An effect also clearly expressed by the 
strongly reduced MARDs for lab 1 versus lab 3 for all the 
ratios (Tables 2 and 3).
For the class II assay, we did not encounter the same bias 
between lab 1 and lab 3 (Figure 1C). The MARD between 
laboratories 1 and 3 for class II (32%, Table 3) was also 
considerably smaller than that for class I (51%, Table 2). 
For class II, none of the STBRs had consistently smaller 
MARDs than the MFI; except STBR-2, the STBRs had a 
between-laboratories variability comparable to the raw 
MFI. We therefore conclude that STBRs seem very useful 
to mitigate proportional bias, while remaining of compa-
rable variability (MARD between 20% and 35%) to that 
of the raw MFI if no such bias is present.
Assessment of Impact on Graft Survival
In a previous study,3 we found that the impact of SAB-
detected DSA on death censored graft survival, adjusted 
for differences in other covariables, is most pronounced in 
transplants with grafts from deceased donors. In this study, 
bead positivity was determined according to manufac-
turer instructions. A lot-specific background MFI per bead 
(range 150–400) was provided, to be subtracted from the 
raw MFI value (referred to as the BCM value). In addition, 
2 ratios were to be calculated: the BCR as the BCM divided 
by the lowest MFI of all beads with antigens of the same 
TABLE 3.
MARD in HLA class II SAB measurements (MFI and various STBRs) between laboratories, together with the MCV for all 
laboratories, in the critical range of average MFI between 500 and 5000
  STBRs
LSA2 (500 < MFI < 5000) MFI STBR-2 STBR-3 STBR-4 STBR-5 STBR-6
Lab 1 vs lab 2, MARD 32.8% 42.2% 31.1% 33.5% 22.0% 24.5%
Lab 1 vs lab 3, MARD 31.9% 31.0% 19.4% 22.2% 15.3% 25.7%
Lab 2 vs lab 3, MARD 22.9% 41.5% 35.6% 32.3% 30.4% 29.9%
All laboratories, MCV 18.4% 24.6% 17.8% 18.1% 14.2% 17.2%
STBRs: see Table 1 for the description of the different ratios.
MARD, mean absolute relative difference; MCV, mean coefficient of variation; MFI, median fluorescence intensity; SAB, single-antigen bead; STBR, signal-to-background ratio.
TABLE 2.
MARD in HLA class I SAB measurements (MFI and various STBR) between laboratories, together with the MCV for all 
laboratories, in the critical range of average MFI between 500 and 5000
  STBRs
LSA1 (500 < MFI < 5000) MFI STBR-2 STBR-3 STBR-4 STBR-5 STBR-6
Lab 1 vs lab 2, MARD 21.2% 21.8% 19.7% 17.1% 14.4% 19.0%
Lab 1 vs lab 3, MARD 50.7% 27.6% 27.2% 27.2% 27.7% 28.4%
Lab 2 vs lab 3, MARD 31.5% 33.6% 33.0% 31.0% 28.8% 32.8%
All laboratories, MCV 22.6% 18.0% 17.4% 16.5% 15.7% 17.5%
STBRs: see Table 1 for the description of the different ratios.
MARD, mean absolute relative difference; MCV, mean coefficient of variation; MFI, median fluorescence intensity; SAB, single-antigen bead; STBR, signal-to-background ratio.
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locus, and the AD-BCR as the BCR divided by the relative 
amount of antigen coated on the bead. When 2 of the 3 val-
ues (BCM, BCR, AD-BCR) are above a certain lot-specific 
threshold, respectively, 1500, 3, and 4 for the lots that we 
used, the bead is deemed positive. With bead positivity, as 
suggested by the manufacturer, we found that the 13% of 
transplants positive for DSA in pretransplant serum have 
a 5% poorer death-censored and covariable-adjusted graft 
survival after 1 year and 16% after 10 years (Figure 2).
In the current study, we evaluated the impact of differ-
ent cutoff levels for absolute MFI measurements, a range 
of STBRs, and combinations thereof on death-censored 
and covariable-adjusted graft survival. We did not find a 
strong or even nondecreasing relationship between abso-
lute MFI cutoff and graft survival difference between the 
resulting DSA-positive and DSA-negative transplants, both 
when the MFI was evaluated as median and 5% trimmed 
mean (Figure 3A). The dotted lines in Figure 3 represent the 
reference cutoff as determined according to the manufac-
turer’s instructions as depicted in Figure 2: 5% difference 
in 1-year graft survival (green), 16% difference in 10-year 
graft survival (purple), and 13% DSA-positive transplants 
for the manufacturer’s cutoff. A strong increase is visible 
in both short- and long-term graft survival differences 
between transplants with and without DSA when the MFI 
cutoff is increased to a value of 750 to 1000, with a (local) 
maximum around an MFI of 2500 (based on the previous 
section, we would like to stress that these values are labo-
ratory specific and do not hold in general). With the cutoff 
increasing from 2500 to 10 000, the 1-year graft survival 
difference decreased, however. The 10-year graft survival 
difference between DSA-positive and  -negative transplants 
did not increase for cutoffs between 2500 and 10 000 either 
and was actually 5% lower for a cutoff around 5000. The 
percentages of DSA-positive transplant for each MedianFI 
or TMeanFI cutoff value are shown in Figure 3B.
BA
C D
FIGURE 1. A, SAB class I MFIs of lab 1 plotted against those of lab 2 (red) and 3 (blue). B, SAB class I STBR-6 values using bead of 
the same HLA locus with lowest MFI as background of lab 1 plotted against those of lab 2 (red) and 3 (blue). C, SAB class II MFIs of lab 
1 plotted against those of lab 2 (red) and 3 (blue). D, SAB class II STBR-6 values of lab 1 plotted against those of lab 2 (red) and lab 3 
(blue). MFI, median fluorescence intensity; SAB, single-antigen bead; STBR, signal-to-background ratio.
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A much clearer relationship between cutoff level 
and graft survival difference was found for the STBRs 
(Figure 3C), especially with respect to short-term survival. 
For all STBRs, the 1-year graft survival difference is nonde-
creasing (STBR-4 and STBR-5) or even increasing (STBR-1 
and STBR-6) with increasing cutoff value. The MFI of the 
bead of the same HLA locus with lowest MFI as back-
ground provided the most stable relationship between 
cutoff and 1-year graft survival; the MFI of the negative 
control bead as background led to a much less consistent 
relationship. Whereas for STBR-1, no robust relationship 
was found either between cutoff value and 10-year graft 
survival difference, STBR-4, STBR-5, and STBR-6 showed 
a much more stable relationship. The STBR-4 and STBR-5 
ratios showed a decrease in 10-year graft survival differ-
ence for higher cutoff values. The 10-year graft survival 
difference remained much more stable for STBR-6. Of all 
the STBRs, the bead of the same HLA locus with lowest 
MFI therefore seems to provide the preferable background 
signal for risk stratification based on short- and long-term 
graft survivals.
In Figure  3C, we evaluated MFI measurements rela-
tive to background signals we considered to be negative. 
The SAB kit, however, also contained a positive control 
bead, coated with human IgG. We next investigated the 
potential additional value of expressing the MFI measure-
ment of a bead relative to the MFI of this positive control 
bead. To this end, we calculated 2 additional ratios. The 
first, STBR-7, was derived as the MFI of a specific bead 
divided by the MFI of the positive control bead. In the sec-
ond, STBR-8, the relative position of the MFI of a specific 
bead was determined between the negative (set to 0) and 
the positive control bead (set to 1) (Figure 3E). The rela-
tionship between cutoff level and graft survival difference 
was highly comparable to the one found for raw MFI cut-
offs (Figure 3A), both, and short- and long-term for both 
ratios. The MFI of the positive control bead therefore did 
not seem to be of additional value in the bead positivity 
assessment.
Background MFIs can be extremely low; for exam-
ple, we encountered values as low as 2 in our data set. 
When working with STBRs, such low background signals 
lead to beads with low MFIs (eg, in the range of 50–100) 
being assessed as positive, even if a high ratio cutoff level 
is chosen. We therefore investigated if requiring a mini-
mum MFI level in addition to ratio cutoff would be of 
additional value. We combined all STBR cutoffs with 
MFI cutoffs between 500 and 3000. For the STBR-6 ratio 
cutoff, we again found the clearest and most stable rela-
tionships between cutoff level and graft survival differ-
ence, displayed in Figure  3D for additional MFI cutoffs 
of 500, 1000, 2000, and 3000. For smaller STBR-6 ratio 
cutoff levels, having an additional MFI cutoff resulted in 
a strong increase in graft survival difference between the 
DSA-positive and -negative groups and a strong decrease 
in DSA positivity. Yet the higher the MFI cutoff taken, the 
more this cutoff will start to dominate in the bead positiv-
ity assessment, whereas from Figure  3A and B, it seems 
clear that a dominant MFI cutoff would not be desirable. 
We would therefore advise a modest MFI cutoff level of 
around 500 in addition to an STBR cutoff. For higher 
STBR cutoff levels (above 10), additional MFI cutoffs do 
not positively impact short- and long-term graft survival 
differences anymore and mainly lead to less transplants 
classified positive for DSA.
This brings us to a final criterion in the cutoff selection 
that has received only modest attention so far: DSA posi-
tivity. We have shown that when working with the STBR-6 
ratio, the higher the cutoff value used, the higher the graft 
survival difference between resulting DSA-positive and 
-negative transplants. At the same time, the percentage of 
transplants classified positive for DSA (strongly) decreases 
of course with increasing the cutoff. Therefore, in choosing 
an appropriate cutoff level for risk stratification, a balance 
needs to be sought between impact (in this case graft sur-
vival difference) on the one hand, and prevalence (% DSA 
positive) on the other.
Figure 3B, D, F, and H represent the percentage of DSA-
positive transplants for different cutoffs. Which cutoff 
provides the appropriate balance between impact and prev-
alence is a managerial problem rather than a mathematical 
one. Nonetheless, from a mathematical perspective, we can 
provide the following input: we found the STBR-6 ratio 
cutoffs (MFI of a specific bead divided by bead of the same 
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FIGURE 2. Adjusted Kaplan-Meier death-censored graft survival estimates according to the presence of pretransplant donor-specific 
HLA antibody (DSA) cutoff determined according to manufacturers’ instructions. The impact of various cutoffs was related to the 
difference in graft survival of 5% at 1 year (green) and of 16% at 10 years after transplant for 430 (13%) of 3237 DSA-positive transplants.
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FIGURE 3. A, Relationship between difference in graft survival 1 (green) and 10 (purple) years after transplant for absolute MFI cutoffs 
(median and 5%-trimmed mean) with (B) the corresponding percentage of DSA-positive transplants (red). The dotted lines represent the 
reference cutoff as determined according to manufacturer’s instructions and also depicted in Figure 2: 5% difference in 1-year graft survival 
(green); 16% difference in 10-year graft survival (purple), and 13% DSA-positive transplants for the manufacturer’s cutoff. C, Relationship 
between difference in graft survival 1 (green) and 10 (purple) years after transplant for STBR cutoffs: STBR-1 using the negative control 
beads as background MFI, STBR-4 using the average MFI of the lowest 5-bead measurements as background MFI, STBR-5 using the 
average MFI of the lowest 10-bead measurements as background MFI, and STBR-6 with background MFI with the bead of the same 
HLA locus with lowest MFI, with (D) the corresponding percentage of DSA-positive transplants (red). E, Relationship between difference in 
graft survival 1 (green) and 10 (purple) years after transplant for STBR-7 (using positive control bead) and STBR-8 (using the negative and 
positive control bead) with (F) the corresponding percentage of DSA-positive transplants (red). G, Relationship between difference in graft 
survival 1 (green) and 10 (purple) years after transplant for STBR-6 in combination with absolute MFI cutoffs with (H) the corresponding 
percentage of DSA-positive transplants (red). See Table 1 for a detailed description of the various STBRs with the background used for 
the calculation. DSA, donor-specific HLA antibody; MFI, median fluorescence intensity; STBR, signal-to-background ratio.
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HLA locus with lowest MFI) to have the clearest and most 
stable relationship with short- and long-term graft survival 
differences. In Figure 3C, we see that from an STBR-6 cut-
off of 15 and higher, the graft survival difference is stabiliz-
ing (no increase in graft survival difference with decreasing 
% DSA–positive patients, Figure 3D). To avoid clear false 
positives, one could consider combining the STBR-6 ratio 
cutoff with an MFI cutoff. From Figure 3G and H, we can 
derive that when an STBR-6 cutoff of 15 is combined with 
an MFI cutoff of 500 or 1000, the same balance between 
graft survival difference and DSA positivity can be reached 
while greatly reducing the risk of false positives. In fact, 
the addition of the absolute MFI cutoff of 500 to an LRA 
cutoff of 15 resulted in our cohort in the reclassification 
of 1 transplant from DSA-positive to -negative only (with 
an MFI of 296 for the bead initially leading to DSA posi-
tivity). Figure S3 (SDC, http://links.lww.com/TP/B601) 
provides a comparison of the reference cutoff (based on 
manufacturers’ recommendation), and the STBR-6 cutoff 
of 15 is combined with an MFI cutoff of 500.
DISCUSSION
Different cutoffs for DSA positivity are used in the lit-
erature that are not based on actual results but just on 
the experience in the different HLA laboratories and 
transplant centers. Previously, we showed that the pres-
ence of pretransplant SAB-defined DSA is associated with 
increased risk of graft failure.3 However, risk stratification 
based on pretransplant DSA can be further improved by 
selecting an optimal clinically relevant cutoff for DSA posi-
tivity based on graft survival results. Inclusion of de novo 
DSA could also improve risk stratification; unfortunately, 
we were not able to investigate this. The data presented in 
this article show the STBR-6 ratio, the MFI of a specific 
bead divided by the lowest MFI of all beads of the same 
HLA locus, to be more robust (across different laborato-
ries) and better related to inferior graft survival for DSA-
positive patients than absolute MFI measurements. The 
combination with a low MFI cutoff around 500 avoids 
false positivity due to exceptionally low MFI measurement 
of the background signal (lowest beads of the same locus, 
probably self-antigen). When applying the manufacturer’s 
instructions for SAB bead positivity assessment, 13% of 
the deceased-donor transplants in our cohort are regarded 
as positive for pretransplant DSA, with, respectively, a 5% 
and 16% lower death-censored and covariable-adjusted 
graft survival than transplants negative for DSA. For risk 
stratification, we propose an STBR-6 cutoff of 15 com-
bined with an MFI cutoff around 500. With this combined 
cutoff, the focus is redirected on 8% of the deceased-donor 
transplant now positive for DSA, with, respectively, 7% 
and 21% difference in 1- and 10-year graft survivals.
All results discussed are based on assays performed with 
SAB kits of 1 manufacturer and cannot be extrapolated 
to kits of another manufacturer. However, as the STBR-6 
uses the bead of the same HLA locus with lowest MFI as 
background, this calculation could also be performed for 
the other vendor’s kit. We evaluated sera from just before 
the transplant, not (necessarily) peak sera. The results we 
would have obtained using peak sera might have been dif-
ferent. We acknowledge that antibody-mediated rejection 
(AMR) would have been a far better criterion to assess 
clinical relevance of SAB measurements than the even-
tual graft survival, which is influenced by so many other 
important factors. Unfortunately, AMR information was 
not available in this retrospective study. Another limita-
tion of the study is that the sera were prescreened with the 
Lifescreen deluxe assay, and only the positive sera were 
tested with the SAB assay. Using this strategy, quite weak 
DSA might have been missed as the screening assay has 
a lower sensitivity. Finally, as the presence of DSA was 
assigned using serological spilt-level donor HLA typing, 
it is possible that some HLA antibodies are in fact not 
donor-specific.
In our previous study,3 we did not observe an effect on 
the number of DSAs on graft survival; therefore, we did 
not further analyze what the impact on graft survival and 
the number of DSAs would be using a different cutoff 
strategy. As the combination of DSA class I and/or II was 
already relatively low using the manufacturer’s cutoff, we 
did not further investigate the different STBRs because 
the numbers will get even lower with increasing cutoff. In 
this study, we only evaluated equal cutoff for both SAB 
class I and II assays. The effect of different MFI cutoffs 
and STBR-6 cutoffs is shown in Figure S1 and Figure S2 
(SDC, http://links.lww.com/TP/B601), respectively. From 
these results, it seems that using a higher MFI cutoff for 
class II compared with class I appeared more optimal, 
as higher cutoff showed larger graft survival difference 
(Figure S1A and B, SDC, http://links.lww.com/TP/B601; 
the above diagonal graft survival differences are consid-
erably higher than those below the diagonal). However, 
none of the combinations of different MFI cutoffs for 
class I and II had a better performance than the combined 
STBR-T MFI cutoff we propose above. Furthermore, the 
STBR-6 ratios do not suffer from asymmetry in results 
when different cutoffs are used for SAB class I and class 
II assays (Figure S2A and B, SDC, http://links.lww.com/
TP/B601).
We noticed for both MFI measurements and investi-
gated ratios a relatively limited impact of the cutoff level 
on the decreased graft survival of DSA-positive transplants. 
When leaving the lower range of cutoffs out of considera-
tion, the 1-year graft survival difference fluctuates around 
7%, and the difference 10 years after transplant is around 
20%. If the cutoff level would be positively related to the 
amount of specific antibody present in the tested serum, 
then it appears that mainly the presence of DSA would 
be of influence on graft survival rather than the amount. 
On the other hand, we did observe a weak relationship 
between cutoff level and 1-year graft survival difference 
for the STBR-6 ratio, a relationship that might have shown 
to be stronger if we would have been able to look at AMR 
instead of graft survival.
In conclusion, in this study, we show that the interas-
say variability can be greatly reduced and stabilized to 
an average absolute relative difference between 20% and 
35%, when working with STBR instead of absolute MFIs. 
This normalization makes it possible to choose a uniform 
STBR cutoff that can be used across different laborato-
ries. Application of the STBRs also resulted in the clearest 
and most stable relationship between DSA positivity and 
inferior 1- and 10-year covariable-adjusted graft survivals. 
With respect to risk stratification of short- and long-term 
graft survivals, we propose an STBR based on STBR-6 
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with a cutoff level of 15 combined with an MFI cutoff 
around 500. For this cutoff, the 1- and 10-year graft sur-
vivals are 8% and 21% poorer, respectively, for the 8% of 
the transplants classified positive for DSA.
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